SCHEMBL1319712

SCHEMBL1319712

N#Cc1ccc2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 8/20 0.49
BRD1 O95696 6/20 0.49
BRPF3 Q9ULD4 5/20 0.49
BRD4 O60885 3/20 0.49
BRD9 Q9H8M2 3/20 0.49
ATIC P31939 1/20 0.47
CYP3A4 P08684 4/20 0.47
CYP2D6 P10635 2/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
PGR P06401 1/20 0.46
ACLY P53396 1/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BRD7 Q9NPI1 1/20 0.45
AVPR2 P30518 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318489 0.96 BRPF1 (0.50) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL29561475 0.83 KDM1A (0.59) BRD4ATICCYP3A4CYP2D6PSEN1
SCHEMBL1319034 0.79 CYP3A4 (0.50) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL28316252 0.76 LMNA (0.69) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL1110645 0.76 AKR1C3 (0.59) CYP3A4PGRACLYLMNASMN1; SMN2
SCHEMBL1321695 0.75 SLC22A12 (0.50) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL1110453 0.75 CHEK2 (0.48) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL1110524 0.74 PGR (0.54) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL12230253 0.73 ATM (0.67) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL1110316 0.73 PLAU (0.57) CYP3A4PGRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 BRPF1 3387/4885BRD1 2773/4885BRPF3 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.